The US pharmaceutical trade association (PhRMA) asked CRA to identify concrete evidence-based proposals on market reforms aimed at creating a more competitive ‘off-patent’ sector in order to generate savings for the Italian National Health Services (SSN).
Working with industry participants, we assessed the potential policy alternatives based on an assessment of the economic and the political realities of the Italian market. This resulted in five potential policy options ranging from tougher enforcement of current generic policy to reforming the incentives for different distribution.
CRA Insights
Market reform in Italy
January 7, 2009
Upcoming events
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...
ThoughtLeaders4: 3rd Annual UK Competition Law
CRA is a proud sponsor of the summit. Simon Chisholm is a speaker during the session titled “Understanding Lessons and Takeaways from Market Investigations”...
